T
Translational Development Acquisition Corp.
TDACUCIK 0001926599NasdaqEmerging GrowthBlank ChecksFY ends Dec 31
Period
FY 2025
Revenue
—
Net Income
$6.36M
Total Assets
$181.70M
Equity
$-6.54M
Shares Out
0
Op. Cash Flow
$-608.4K
Business
Translational Development Acquisition Corp. is a blank check company formed to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. It offers units consisting of Class A ordinary shares and redeemable warrants issued in an IPO and related private placement, and maintains proceeds in a U.S.-based trust account. Its operations are organized around identifying, structuring and consummating an initial business combination and managing related shareholder redemption and trust-account processes. It sources targets through relationships with venture capital, growth equity, investment banks, company executives and other intermediaries.
Summary from filing dated 2025-03-31
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| General and administrative costs | 944,538 | 196,358 | — | |
| Loss from operations | −944,538 | −196,358 | −485,550 | |
| Dividends earned on marketable securities held in Trust Account | 7 | 125,346 | — | |
| Total other income | 7 | 125,346 | — | |
| Net income (loss) | 6 | −71,012 | −485,550 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Cash | 29,787 | 438,174 | 2,021 | — | |
| Prepaid expenses | 9,678 | 212,059 | — | — | |
| Total Current Assets | 39,465 | 650,233 | 2,021 | — | |
| Marketable securities held in Trust Account | 182 | 174 | 0 | — | |
| TOTAL ASSETS | 182 | 175 | 2,021 | — | |
| Accounts payable and accrued expenses | 162,311 | 16,189 | — | — | |
| Due to Sponsor | 106,762 | 2,000 | — | — | |
| Promissory note - related party | 200,000 | — | 347,500 | — | |
| Accrued offering costs | 75,000 | 192,114 | 160,927 | — | |
| Total Current Liabilities | 544,073 | 210,303 | 509,679 | — | |
| Deferred underwriting fee | 6 | 6 | — | — | |
| TOTAL LIABILITIES | 7 | 6 | 509,679 | — | |
| Commitments and Contingencies (Note 6) | — | — | — | — | |
| Accumulated deficit | −7 | −6 | −532,658 | — | |
| Total Shareholders' Deficit | −7 | −6 | −507,658 | −22,108 | |
| Total Liabilities, Class A Ordinary Shares Subject to Possible Redemption, and Shareholders' Deficit | 182 | 175 | 2,021 | — |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Net Income (loss) | 6 | −71,012 | −485,550 | |
| Payment of operation costs through promissory note | — | 4,719 | — | |
| Dividends earned on marketable securities held in Trust Account | −7 | −125,346 | — | |
| Prepaid expenses | 202,381 | −212,059 | 2,000 | |
| Due to Sponsor | 104,762 | 2,000 | — | |
| Accounts payable and accrued expenses | 29,008 | −449,748 | 1,006 | |
| Net cash used in operating activities | −608,387 | −851,446 | −204 | |
| Investment of cash in Trust Account | — | −174 | — | |
| Net cash used in investing activities | — | −174 | — | |
| Proceeds from sale of Units, net of underwriting discounts paid | — | 169 | — | |
| Proceeds from sale of Private Placements Warrants | — | 7 | — | |
| Proceeds from promissory note - related party | 200,000 | 406,540 | — | |
| Repayment of promissory note - related party | — | −800,000 | — | |
| Payment of offering costs | — | −218,941 | — | |
| Net cash provided by financing activities | 200,000 | 176 | — | |
| Net Change in Cash | −408,387 | 436,153 | −204 | |
| Offering costs included in accrued offering costs | — | 495,872 | 5,830 | |
| Deferred offering costs paid through promissory note - related party | — | 41,241 | 88,500 | |
| Deferred underwriting fee | — | 6 | — | |
| Offering costs charged to additional paid-in capital | — | 756,054 | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro